<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5426">
  <stage>Registered</stage>
  <submitdate>9/09/2005</submitdate>
  <approvaldate>9/09/2005</approvaldate>
  <nctid>NCT00169546</nctid>
  <trial_identification>
    <studytitle>Study In Airway Physiology In Children SERETIDE DISKUS 速 Inhlaer and FLIXOTIDE速 Inhaler Are Trademarks of GSK Group of Companies.</studytitle>
    <scientifictitle>Randomised, Double-blind Parallel Group Study to Assess the Bronchodilative and Bronchoprotective Properties of SERETIDE DISKUS 速 Inhlaer 50/100mcg Twice Daily vs. FLIXOTIDE速 Inhaler 200mcg Twice Daily.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>SAM40100</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Salmeterol/fluticasone propionate
Treatment: drugs - Fluticasone propionate

Experimental: Arm 1 - 


Treatment: drugs: Salmeterol/fluticasone propionate


Treatment: drugs: Fluticasone propionate


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>sRAW (k.Pa.s) measured before the study medication dose at the end of treatment (week 6)</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>sRAW measured pre-dose at Week 3. sRAW measured 48 hours after last study medication dose. % symptom-free days over Weeks 1-6. % symptom-free nights over Weeks 1-6. Type and frequency of adverse events.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Currently receiving 200-800mcg/day beclomethasone dipropionate.

          -  sRAW value of 1.3 kPa's.</inclusivecriteria>
    <inclusiveminage>4</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>11</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  3 or more courses of oral steroids in last 12 months.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>64</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2005</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Lancashire</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Comparison of two asthma treatments by lung function measures.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00169546</trialwebsite>
    <publication>This study has not been published in the scientific literature.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>